KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $26.3 million.

  • Supernus Pharmaceuticals' Other Accumulated Expenses changed N/A to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year change of. This contributed to the annual value of $4.3 million for FY2023, which is 7460.12% down from last year.
  • Supernus Pharmaceuticals' Other Accumulated Expenses amounted to $26.3 million in Q3 2025.
  • Supernus Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $27.7 million during Q2 2025, with a 5-year trough of $710000.0 in Q3 2023.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $8.1 million (2022), whereas its average is $10.6 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Other Accumulated Expenses tumbled by 9132.77% in 2023 and then skyrocketed by 66469.78% in 2025.
  • Supernus Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $20.1 million in 2021, then dropped by 16.24% to $16.9 million in 2022, then tumbled by 74.6% to $4.3 million in 2023, then fell by 15.41% to $3.6 million in 2024, then surged by 626.52% to $26.3 million in 2025.
  • Its Other Accumulated Expenses was $26.3 million in Q3 2025, compared to $27.7 million in Q2 2025 and $4.7 million in Q1 2025.